Designing tradable ETF architecture for the next industrial cycle.
Horizon Oasis Limited is an emerging financial innovation company. We do not simply study how AI changes industries; we translate those shifts into verifiable methodologies, ETF-ready structures, and cross-border capital platforms that institutional investors can review. Our core mission is to make industrial transformation understandable, allocable, and investable.
Backtest simulation only — not verified live returns. See footer for full disclaimer.
Horizon Oasis integrates AI-industry data, volatility risk premium, index methodology, and ETF issuance pathways into one evolving platform.
Company Thesis
Capital markets are moving from buying a theme to owning a verifiable industrial logic. Horizon Oasis is positioned as the designer, issuance coordinator, and long-term methodology platform for AI-industry ETFs: we translate industrial insight into rules, rules into indexes, indexes into products, and products into globally accessible capital structures.
Investment Philosophy
We do not invest in short-term themes. We invest in the process by which AI reprices industries.
AI is no longer merely a technology-sector narrative. It is becoming a capital expenditure cycle across healthcare, energy, industrials, and financial services. As companies deploy AI, markets reassess growth, efficiency, risk, and volatility. Horizon Oasis exists to institutionalize that repricing process.
01
Industrial cycles come before product cycles
An ETF should not merely package popular stocks. It should express a real shift in how capital is being allocated within an industry. We define the causal logic of industrial transformation before we define portfolio construction, index weighting, and risk controls.
02
Explainable AI is more valuable than mysterious AI
AI is not a black-box label in our platform. It is a research augmentation layer used to scan data, test scenarios, monitor signals, and accelerate methodology iteration. Investment decisions must still be written as rules, backtested, and reviewed.
03
Income should come from structure, not only direction
We focus on dividends, interest, option premium, and volatility risk premium because these income sources can be defined, stress-tested, and risk-layered. Directional upside is valuable, but structural income is the portfolio foundation.
04
Risk management must exist before the product exists
Every ETF or strategy should carry its risk logic inside the methodology before launch: liquidity thresholds, volatility conditions, momentum overheating, cash pivots, and downside protection should not be afterthoughts.
05
Transparency is the long-term moat of financial products
Institutional investors need to understand why a strategy works, not only how much it returned. Strategy documentation, index methodology, backtest assumptions, scenario analysis, and live trading data are part of the platform's value.
ETF Issuance Platform
From one industrial insight to an ETF capable of reaching the public market.
Horizon Oasis is not a single-fund concept. It is a replicable issuance pipeline. We break down the impact of AI across industries into investable hypotheses, then translate them into indexes, strategies, legal structures, white-label ETF partnerships, and market distribution.
Platform Core
AI Industry Research Engine
We track AI deployment intensity, capital expenditure, revenue conversion, and valuation repricing across healthcare, energy, industrials, and financial services to identify durable investment themes.
Index Layer
Index and Methodology Design
We define constituent selection, weighting, rebalancing, option overlays, cash allocation, and risk triggers so each strategy can be reviewed and replicated by third parties.
Product Layer
ETF Issuance and White-Label Partnerships
Through white-label ETF partners, exchange filing pathways, calculation agents, and compliance documentation, strategies can move toward tradable listed products.
Capital Layer
Seed Capital and Founding LPs
We seek to establish live trading records through managed accounts or Cayman SP structures before using GIPS readiness, AUM scale, and institutional due diligence to support ETF launch.
Distribution Layer
Cross-Border Capital Channels
We connect Asia-based family offices, RIAs, research partners, and global ETF platforms so strategies can move from research documents to real allocation conversations.
Expansion Layer
Multi-Industry ETF Pipeline
The same framework can extend into Energy-AI, Industrial-AI, Financial-AI, and other verticals, forming a family of AI-industry ETF strategies.
Flagship Strategy
AIHCI: the first verifiable expression of the AI-industry ETF platform.
The AI-Enhanced Healthcare Income Index is the clearest flagship output of the Horizon Oasis platform today. Healthcare has high data density, regulatory friction, clinical catalysts, and long-term demographic demand, making it a compelling vertical for structural implied-volatility premium.
6–8%Target annualized yield, designed for monthly distribution
1.31Base-case Sharpe ratio, simulated backtest data
-17.1%Base-case max drawdown, compared with SPY -34%
25.1%Base-case CAGR, 2018–2025 simulated backtest
The figures above are based on 2018–2025 simulated backtests and model-based option pricing. They do not represent actual trading performance. Live results may differ due to liquidity, slippage, transaction costs, actual option quotes, and market impact.
01
AI-Enabled Healthcare Universe
A curated universe of 11 vertical-market equities positioned to benefit from AI's real capital deployment cycle. The structure separates Tier 1 blue-chip leaders from a defensive dividend layer, with the objective of focusing on an effective pool for structural implied-volatility premium harvesting.
02
Three-Gate Adaptive Overlay Protocol
The strategy is designed to reduce the capital erosion risk of mechanical covered-call programs. Before execution, it applies a Liquidity Gate, VRP Gate, and Momentum Gate. When a constituent enters a short-term momentum breakout, the overlay can be suspended to preserve upside participation.
03
Section 7 Cash Pivot Mechanism
In extreme bull-market or low-volatility environments, the system can activate an adaptive pivot: increasing the short-term Treasury cash sleeve from 10% to 15% and referencing the U.S. 3-month Treasury bill rate to support recurring cash-flow stability.
Methodology Loop
We are not launching one product. We are operating a repeatable ETF-generation system.
Each theme must pass through the same sequence: industrial hypothesis, data validation, rule encoding, stress testing, documentation, live trading record, and ETF issuance. This allows Horizon Oasis to replicate a process rather than restart from zero.
01 Sense
Detect industrial repricing
Track AI deployment, corporate capital expenditure, regulatory events, supply-chain shifts, and market volatility to confirm whether a theme has multi-year investment logic.
02 Encode
Convert views into rules
Translate the investment hypothesis into constituents, weights, overlay ratios, thresholds, and rebalance rules so the strategy can be programmed and reviewed.
03 Augment
Use AI to expand research capacity
Machine-assisted analysis accelerates data scanning, scenario comparison, risk-signal detection, and methodology iteration while preserving human governance and explainability.
04 Stress
Test across market regimes
Evaluate strategies across multi-year, multi-regime data and disclose assumptions, model limits, slippage, and potential differences between simulation and live trading.
05 Institutionalize
Build an institutional-grade record
Use managed-account execution to establish live trading data while preparing for GIPS readiness, third-party methodology review, and institutional due diligence.
06 Launch
Advance toward ETF issuance
Once a strategy has record, scale, and documentation, it can enter the white-label ETF partnership, exchange filing, and listing pathway.
Path to Institutional Grade
From founding LPs, to live trading records, to ETF listing.
Horizon Oasis is built around staged risk reduction for institutional investors: first prove that the strategy can trade, then prove that the record can be reviewed, and only then advance toward ETF filing.
MVT Managed Account
Target a $5M founding LP round, establish a Cayman SP or managed account, complete trading accounts, data feeds, and three-gate execution systems, and begin accumulating live trading records.
GIPS & Scale
Upgrade to OptionMetrics or equivalent real option data, prepare GIPS pre-verification, engage Asia family offices and U.S. RIAs, and target a path toward $50M AUM.
White-Label ETF Launch
Work with ETF white-label partners, exchanges, legal counsel, and calculation agents to pursue NYSE Arca or Cboe BZX filing while initiating the next vertical AI ETF methodology.
HORIZON OASIS LIMITEDResearch · Index Methodology · ETF Issuance · Cross-Border Capital
AIHCI ETFAI-Enhanced Healthcare Income
Flagship strategy designed around structural volatility risk premium in AI-enabled healthcare equities, with a monthly-income ETF pathway.
Flagship
Energy-AI ETFPipeline Concept
Focused on AI's impact on power demand, energy infrastructure, data-center load, and energy-efficiency investment cycles.
Pipeline
Industrial-AI ETFPipeline Concept
Focused on automation, machine vision, supply-chain software, robotics, and the long-term investment theme of industrial efficiency.
Pipeline
Industry News Summary
Signals from the AI-industry capital cycle, tracked as they happen.
A running log of the market, regulatory, and capital-markets events that inform AIHCI's methodology and the broader Horizon Oasis thesis. Curated from daily research and published as concise, sourced notes — not investment advice.
Healthcare AI
Eli Lilly Launches Medicare GLP-1 Bridge Program as LLY Reaches All-Time High, Healthcare Sector Outperforms
Effective July 1, 2026, Eli Lilly (NYSE: LLY) activated its Medicare GLP-1 Bridge program, enabling eligible Medicare Part D beneficiaries to access Foundayo (orforglipron) — the company's once-daily oral GLP-1 pill — and Zepbound (tirzepatide) for obesity at $50 per month with prior authorization. The program launch follows Lilly's announcement of more than $20 billion in biotech M&A across oncology, neuroscience, cardiovascular disease, gene editing, and vaccines in 2026. Shares of LLY reached an all-time high on June 26, driving the healthcare sector to outperform the broader S&P 500; LLY's market capitalization now exceeds $1.07 trillion.
Why it matters: The Medicare GLP-1 Bridge program represents the convergence of AI-optimized pharmaceutical development with large-scale payor access — a concrete commercial milestone for one of AIHCI's core constituents. LLY's simultaneous all-time high, $1 trillion-plus market cap, and $20B+ acquisition pipeline illustrate the durable fundamental momentum underlying the AI-enabled healthcare thesis: companies using AI-accelerated drug discovery and delivery are generating both earnings growth and elevated implied volatility, the twin inputs that make AIHCI's covered call income engine function.
Source: Eli Lilly company announcement; GuruFocus; Yahoo Finance (July 1, 2026)
Healthcare AI
Danaher's Masimo Wins FDA Clearance for AI-Enabled Opioid-Induced Respiratory Depression Detection
On June 22, 2026, Masimo — a Danaher (NYSE: DHR) company — received FDA 510(k) clearance for an AI-enabled opioid-induced respiratory depression detection feature integrated into its Radius VSM wearable continuous patient monitor. The clearance adds a real-time, algorithm-driven respiratory-distress alert to a device already used in hospital and post-surgical monitoring settings, following Danaher's integration of Masimo's monitoring portfolio since completing its $9.9 billion acquisition of the company.
Why it matters: This is another concrete instance of AI moving from research claim to a cleared, deployed clinical feature inside a mainstream patient-monitoring device — the same deployment-intensity signal AIHCI's research process tracks when assessing whether a constituent's AI narrative is backed by real regulatory and commercial traction, not just a thematic label. It also illustrates how consolidation such as Danaher's Masimo acquisition can function as a distribution channel for AI-enabled medical technology, extending the deployment thesis beyond pure-play device makers into diversified life-sciences platforms.
Source: FDA 510(k) clearance database; company disclosures (clearance dated June 22, 2026)
M&A
Merck KGaA to Acquire Bio-Techne for $11.3 Billion, Its Largest Deal Since 2014, Betting on Life-Sciences Research Tooling
On June 25, 2026, Merck KGaA agreed to acquire Bio-Techne Corporation (Nasdaq: TECH) for $73 per share in cash — a roughly 36% premium to the one-month volume-weighted average price — in a transaction valued at approximately $11.3 billion, Merck KGaA's largest acquisition since its $17 billion purchase of Sigma-Aldrich in 2014. Bio-Techne supplies foundational life-sciences research inputs, including recombinant proteins, antibodies, and RNAscope spatial biology technology, that increasingly underpin AI-driven biological discovery pipelines across the industry. The transaction is expected to close in late 2026 or early 2027, subject to Bio-Techne shareholder and regulatory approval.
Why it matters: A near-36% takeover premium for a life-sciences tools supplier is concrete evidence that strategic acquirers are paying up for the data and reagent infrastructure that increasingly feeds AI-enabled drug discovery — the same deployment-intensity signal AIHCI's research process tracks across its constituents. It also reinforces a thesis adjacent to AIHCI's core holdings: capital is consolidating around the picks-and-shovels layer of AI-driven life sciences, not only around AI software and diagnostics themselves.
Source: Merck KGaA company disclosure; Lawrence, Evans & Co. weekly healthcare M&A digest (deal agreed June 25, 2026)
AI Infrastructure
OpenAI IPO-Delay Report Triggers Broad AI Stock Sell-Off as Healthcare Names Hit New Highs
On June 26, 2026, U.S. and Asian equity markets saw a broad sell-off in AI-infrastructure and chip-related names after The New York Times reported that OpenAI's advisers had presented CEO Sam Altman with the option of delaying the company's IPO to 2027 rather than accept a valuation below its roughly $1 trillion target. SoftBank Group, one of OpenAI's largest backers, fell more than 12% in Tokyo trading, while NVIDIA (NASDAQ: NVDA) declined for a second consecutive session, leaving it down roughly 10% over the trailing month and in technical correction territory; the S&P 500 closed roughly flat at 7,354.02. The same day, UnitedHealth Group (NYSE: UNH) closed at a fresh 52-week high of $417.58 and Eli Lilly (NYSE: LLY) touched an all-time high, continuing a rotation of capital toward defensive, AI-enabled healthcare names.
Why it matters: The episode is a live illustration of the distinction at the core of AIHCI's design: exposure to AI's real-economy deployment inside healthcare, rather than to the financing and valuation risk concentrated in pure AI-infrastructure equities. As questions about AI capex returns resurface, the same trading session produced fresh highs in two of AIHCI's largest constituents — at least in this instance, evidence that the strategy's structural diversification logic functioned as intended.
Source: The New York Times; CNBC; TheStreet (June 26, 2026)
Healthcare AI
Veeva Launches Falcon MLR, Bringing Agentic AI Into Life-Sciences Content Review
On June 23, 2026, Veeva Systems (NYSE: VEEV) announced it has acquired Copli, an agentic AI platform for medical, legal, and regulatory (MLR) review, and relaunched it as Veeva Falcon MLR. The company states the product is designed to automate the bulk of manual MLR review work that pharmaceutical and life-sciences commercial teams currently perform by hand, targeting the elimination of 70% or more of that manual labor. The announcement followed Veeva's fiscal Q1 2027 results, in which subscription revenue rose 15% year-over-year to $730.2 million.
Why it matters: This is a concrete example of AI deployment in healthcare moving from research pilots into a recurring, revenue-generating enterprise workflow — the same deployment-intensity signal Horizon Oasis tracks when assessing whether an AI-industry thesis has durable capital-allocation support rather than a temporary narrative. For AIHCI, it reinforces the case that the AI-enabled healthcare universe is broadening beyond diagnostics and devices into operational software.
Source: Veeva Systems company announcement; StockTitan (June 23, 2026)
AI Infrastructure
CME Group to Launch Compute Futures, Backed by a GPU Rental-Rate Index
CME Group and Silicon Data announced a partnership on May 12 to launch the world's first compute futures market, priced off Silicon Data's daily GPU rental-rate benchmark indices, targeted for H2 2026 pending regulatory approval. Reporting indicates competitors such as Architect are preparing similar products, suggesting that "compute as an asset class" is moving from concept to market infrastructure.
Why it matters: The world's largest derivatives exchange beginning to price AI compute as a structured, tradable asset class is institutional-grade validation of the AI-infrastructure investment cycle underpinning the Horizon Oasis thesis.
Source: CME Group, Bloomberg (announced May 12, 2026)
Healthcare AI
FDA Clears GE HealthCare's AI Oncology Contouring Software Under a Continuous-Update Pathway
On June 23, 2026, GE HealthCare Technologies (NASDAQ: GEHC) received FDA 510(k) clearance, supported by a Predetermined Change Control Plan (PCCP), for its MIM Contour ProtegeAI+ 2.0 AI-based auto-contouring software used in radiation oncology treatment planning. The PCCP designation allows future algorithm updates to be deployed under a pre-agreed regulatory framework rather than requiring a new submission for each iteration. Shares of GEHC rose 4.88% on the day.
Why it matters: This is a concrete instance of clinical AI moving from pilot to commercially deployed product with a regulator-sanctioned path for ongoing iteration — the type of single-name, AI-driven catalyst that AIHCI's volatility-risk-premium framework is designed to harvest income around, rather than take a directional view on.
Source: GE HealthCare company disclosures; market reporting (June 23, 2026)
Investor Relations
Seeking founding investors and research partners who understand the next generation of ETFs.
We welcome conversations with institutional allocators, family offices, ETF white-label platforms, research teams, and strategic LPs. AIHCI methodology, backtest reports, business roadmap, and founding LP structure can be made available for further review.